Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Observational study of tislelizumab + zanubrutinib + lenalidomide + obinutuzumab + methotrexate + temozolomide in diffuse large B-cell lymphoma with secondary CNS involvement
ChiCTR2200062052Phase 4Not yet recruiting
- Sponsor
- The First Hospital of Fujian Medical University
- Start
- Jul 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tislelizumab, zanubrutinib, lenalidomide, obinutuzumab, methotrexate and 1 more in diffuse large B-cell lymphoma (DLBCL), sponsored by The First Hospital of Fujian Medical University. Primary endpoint: Objective response rate. Planned start Jul 2022; status: not yet recruiting.
02
Drugs
tislelizumabzanubrutiniblenalidomideobinutuzumabmethotrexate
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on ChiCTR2200062052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200062052.